Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBIT Margin (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EBIT Margin for 13 consecutive years, with 32.29% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin rose 3196.0% to 32.29% in Q3 2025 year-over-year; TTM through Sep 2025 was 40.85%, a 3500.0% increase, with the full-year FY2024 number at 14.29%, down 201084.0% from a year prior.
  • EBIT Margin was 32.29% for Q3 2025 at Theravance Biopharma, down from 10.4% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 10.4% in Q2 2025 to a low of 1540.08% in Q1 2022.
  • A 5-year average of 253.91% and a median of 110.16% in 2024 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: surged 424331bps in 2021, then plummeted -95165bps in 2022.
  • Theravance Biopharma's EBIT Margin stood at 406.36% in 2021, then soared by 71bps to 119.0% in 2022, then skyrocketed by 53bps to 55.82% in 2023, then rose by 12bps to 49.06% in 2024, then skyrocketed by 34bps to 32.29% in 2025.
  • Per Business Quant, the three most recent readings for TBPH's EBIT Margin are 32.29% (Q3 2025), 10.4% (Q2 2025), and 93.8% (Q1 2025).